# Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention

> **NCT02315703** · PHASE1,PHASE2 · COMPLETED · sponsor: **Janssen Vaccines & Prevention B.V.** · enrollment: 393 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** Ad26.Mos.HIV
- **BIOLOGICAL:** MVA-Mosaic
- **BIOLOGICAL:** gp140 DP Low-dose
- **BIOLOGICAL:** gp140 DP High-dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02315703
- **Lead sponsor:** Janssen Vaccines & Prevention B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-22
- **Primary completion:** 2017-08-29
- **Final completion:** 2022-03-28
- **Target enrollment:** 393 (ACTUAL)
- **Last updated:** 2025-02-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02315703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02315703, "Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT02315703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*